Sign in / Join Now
ETFs & Funds
Abraxane data on panc
. SPARC hypothesis controversial. Abrax does not improve
, which is usually SPARC+.
Perhaps destroying SPARC/stroma promotes metastasis - allows for easier malignant cell escape. Abrax should have worked better in breast
Off topic: Did
get halted today? I can't wait to see the Study 301 results!! (the non-carrier one) Or was it the Study 300?
Add a reply...
Latest StockTalks »
people get CELG breaking news and analysis by email alert.
Get email alerts on CELG »
Get latest price
From other sites
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
at Zacks.com (Tue, 8:55AM)
Celgene Sees Much Higher Profits, but Wall Street Still Yawns
at TheStreet (Mon, 12:55PM)
Celgene Corporation Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance
at TheStreet (Mon, 10:45AM)
Celgene Corporation To Announce Fourth Quarter And Full-Year 2016 Results On January 26, 2017
at TheStreet (Jan 4, 2017)
Celgene Corporation To Present At The 35th Annual J.P. Morgan Healthcare Conference
at TheStreet (Jan 3, 2017)